Liang, Xu <br/><br/>
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).  [electronic resource] 

 -  Journal of hematology & oncology  10 2018 
 - 124 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1756-8722 
<br/><br/><label>Standard No.: </label>10.1186/s13045-018-0670-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anastrozole--therapeutic use<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>DNA, Neoplasm--genetics<br/>Female<br/>Fulvestrant--therapeutic use<br/>Gene Expression Profiling<br/>Humans<br/>Lymphocytes, Tumor-Infiltrating--immunology<br/>Neoadjuvant Therapy<br/>Postmenopause<br/>Prognosis<br/>RNA, Neoplasm--genetics<br/>Th1 Cells--immunology